La Jolla Pharmaceutical Company (NASDAQ:LJPC)‘s stock had its “buy” rating restated by analysts at Chardan Capital in a report released on Tuesday. They currently have a $85.00 target price on the biopharmaceutical company’s stock. Chardan Capital’s price target suggests a potential upside of 162.67% from the stock’s current price.

A number of other equities analysts have also recently issued reports on LJPC. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $57.00 price target on shares of La Jolla Pharmaceutical in a research note on Saturday, April 22nd. Noble Financial reiterated a “buy” rating on shares of La Jolla Pharmaceutical in a research note on Sunday, April 30th. Cowen and Company reiterated a “buy” rating and issued a $55.00 price target on shares of La Jolla Pharmaceutical in a research note on Friday, April 28th. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research note on Thursday, June 29th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $40.00 price target on shares of La Jolla Pharmaceutical in a research note on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $51.67.

La Jolla Pharmaceutical (NASDAQ:LJPC) traded up 0.49% on Tuesday, hitting $32.52. 21,107 shares of the company’s stock were exchanged. The firm has a 50 day moving average price of $30.87 and a 200-day moving average price of $28.33. La Jolla Pharmaceutical has a 52-week low of $14.63 and a 52-week high of $39.28. The stock’s market cap is $719.44 million.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.12) by $0.09. La Jolla Pharmaceutical had a negative net margin of 12,692.37% and a negative return on equity of 91.66%. During the same quarter in the prior year, the firm posted ($0.90) EPS. Analysts predict that La Jolla Pharmaceutical will post ($4.96) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/08/chardan-capital-reiterates-buy-rating-for-la-jolla-pharmaceutical-company-ljpc.html.

A number of institutional investors have recently made changes to their positions in LJPC. State Street Corp raised its position in shares of La Jolla Pharmaceutical by 6.3% in the fourth quarter. State Street Corp now owns 227,561 shares of the biopharmaceutical company’s stock worth $3,992,000 after buying an additional 13,495 shares during the period. Teachers Advisors LLC raised its position in shares of La Jolla Pharmaceutical by 12.4% in the fourth quarter. Teachers Advisors LLC now owns 25,390 shares of the biopharmaceutical company’s stock worth $445,000 after buying an additional 2,791 shares during the period. Creative Planning acquired a new position in shares of La Jolla Pharmaceutical during the first quarter worth $288,000. Essex Investment Management Co. LLC acquired a new position in shares of La Jolla Pharmaceutical during the first quarter worth $483,000. Finally, Jennison Associates LLC raised its position in shares of La Jolla Pharmaceutical by 586.1% in the first quarter. Jennison Associates LLC now owns 1,768,213 shares of the biopharmaceutical company’s stock worth $52,781,000 after buying an additional 1,510,504 shares during the period.

About La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Analyst Recommendations for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related companies with MarketBeat.com's FREE daily email newsletter.